Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579087 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577356 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL865066 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL3959220 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577464 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577430 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577467 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL8357720 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL8357002 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL96648 | 0.98 | SIGMAR1 (0.54) | SIGMAR1MAPTRXFP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3017000-B1 | PHENOLIC POLYSULPHIDES HAVING AN IMPROVED ODOUR | ARKEMA FRANCE (FR) | 2024-05-29 | — | — | EP | claimed |
| US-20160130419-A1 | PHENOLIC POLYSULPHIDES HAVING AN IMPROVED ODOUR | ARKEMA FRANCE (FR) | 2016-05-12 | — | — | US | claimed |
| EP-3017000-A1 | PHENOLIC POLYSULPHIDES HAVING AN IMPROVED ODOUR | Arkema France (FR) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001234-A1 | PHENOLIC POLYSULPHIDES HAVING AN IMPROVED ODOUR | ARKEMA FRANCE (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| EP-3017000-B1 | PHENOLIC POLYSULPHIDES HAVING AN IMPROVED ODOUR | ARKEMA FRANCE (FR) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-112250557-A | Method for efficiently synthesizing 1, 6-diene-3-ketone derivative | 徐州工程学院 | 2021-01-22 | — | — | CN | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| WO-1986001208-A1 | STEREOISOMETRICALLY PURE 17-ALPHA-ETHYNYL-ESTRA-2-EN-17BETA-OL AND ESTERS THEREOF | SRI INTERNATIONAL (US) | 1986-02-27 | — | — | WO | disclosed |
| WO-1985005361-A1 | 17abeta-HYDROXY-7alpha-METHYL-D-HOMO-19-NORANDROST-4,16-DIENE-3-ONE AND THE 17-ESTERS THEREOF: METHODS OF PREPARATION AND USES | SRI INTERNATIONAL (US) | 1985-12-05 | — | — | WO | disclosed |
| EP-0053017-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-20 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0126635-A2 | Novel oxindole derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SIGMAR1 4091/4885MAPT 2196/4885RXFP1 2555/4885 |
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | PSMB10, PSMB1, PSMB5 | SIGMAR1 4031/4885MAPT 2616/4885RXFP1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.